IMS Company Profiles - Report Buyer

IMS COM PANY PRO FILES NOVARTIS
Product Class Date Terms of Agreement
QAX 935 R 2005 QAX 935 is a Toll-like receptor 9 (TLR9) agonist
discovered through a research collaboration between
Idera (formerly Hybridon) and Novartis. It is now being
co-developed by Novartis and Idera. In 2005, Hybridon
and Novartis entered into a deal for the discovery,
optimization, development and commercialization of TLR9
immune modulatory oligonucleotide candidates, based on
Hybridon’s proprietary Immune Modulatory
Oligonucleotide (IMO) technology platform, for the
treatment of asthma and allergy. In March 2007, Idera
and Novartis extended the term of the research phase of
their collaboration by one year. Novartis has in-licensed
the exclusive rights to QAX 935 from Idera.
formoterol + mometasone R 2003 Schering-Plough and Novartis agreed to co-develop MFF
258, a combination of Schering-Plough’s corticosteroid
mometasone and the Novartis beta2 agonist formoterol.
gimatecan L 2003 Gained exclusive rights worldwide and semi-exclusive
rights in Italy to Sigma-Tau’s oral topoisomerase I
inhibitor.
fingolimod (FTY 720) L 1997 Exclusive worldwide rights outside Japan licensed-in from
Yoshitomi (now Mitsubishi Tanabe Pharma).
General Research Collaborations
Company/Organization Date Area of
Collaboration
Terms of Agreement
FORMA 2009 Inhibitors in oncology Option and license agreement, through
the Novartis Option Fund. FORMA will use
its biology- and chemistry-based platform
to develop inhibitors of an undisclosed
protein-protein interaction cancer target.
FORMA will receive an upfront fee, and is
entitled to potential milestone payments of
over $200 m in total and royalties. Further
terms of the agreement were not
disclosed.
© 2009 IMS Health In cor po rated or its af fil i ates Page 129